Astal Laboratories FY26 Results: Consolidated Profit at ₹14.71 Crore

Consolidated Revenue: ₹249.13 crore
Consolidated Net Profit: ₹14.71 crore

Reader Takeaway: Stable financial performance for FY26; continuity in internal audit function.

What just happened

Astal Laboratories Limited has released its audited financial results for the fiscal year ending March 31, 2026. The company reported consolidated revenue of ₹249.13 crore and a net profit of ₹14.71 crore. Standalone figures show revenue at ₹155.99 crore and profit at ₹8.12 crore for the same period.

Why this matters

These audited results provide investors with a clear picture of the company's financial health and performance over the past fiscal year. The figures confirm the company's revenue generation and profitability from its core business of manufacturing and trading active pharmaceutical ingredients (APIs).

The backstory

Astal Laboratories operates in the pharmaceutical sector, specifically focusing on the 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)'. The consolidated results incorporate the financials of its wholly-owned subsidiary, Sriven Pharmachem India Private Limited.

What changes now

With the audited results declared, the company has fulfilled its regulatory obligation for the fiscal year. The re-appointment of M/s V R P S & Co. as internal auditors ensures the continuation of financial oversight for the upcoming fiscal year 2026-27.

Risks to watch

As the company operates in a single business segment, diversification risk is minimal. However, reliance on external auditors for consolidated reporting, as mentioned, is a routine aspect of financial consolidation and requires continued scrutiny.

Peer comparison

While specific peer data is not provided in the filing, Astal Laboratories operates in the competitive API manufacturing sector, where margins and regulatory compliance are key differentiators.

Context metrics (time-bound)

• Standalone Revenue FY26: ₹155.9953 crore
• Standalone Net Profit FY26: ₹8.1155 crore
• Consolidated Revenue FY26: ₹249.1273 crore
• Consolidated Net Profit FY26: ₹14.7094 crore

What to track next

Investors should monitor the company's performance in the upcoming quarters, focusing on revenue growth, profit margins, and any updates regarding its subsidiary's contribution to the overall financials.